Most current interest focuses on developing subtype-selective inhibitors of Nav1.7 and arises from genetic data showing that loss of Nav1.7 function significantly attenuates pain, with anosmia the only apparent additional phenotype [8–14]. This evidence concerns the gene SCN9A and Kallmann syndrome.